Emerging Therapies

Asingle infusion of the investigational agent lifileucel—an immunotherapy using cryopreserved autologous tumor-infiltrating lymphocytes (TILs)—induced responses in more than 33% of patients with advanced melanoma whose disease progressed with multiple previous therapies, including PD-1 and BRAF/MEK inhibitors.
The small molecule inhibitor of tyrosine kinase WEE1 adavosertib demonstrated promising clinical activity in a single-arm, phase 2 study of patients with unselected uterine serous cancer (USC), with an objective response rate of 29.4%, said Joyce F. Liu, MD, MPH, Director of Clinical Research, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting.
A novel intratumoral chemotherapy agent delivered by direct injection permits the dispersion of cytotoxic drugs into cancer cells to eradicate tumors.
San Francisco, CA—The combination of nivolumab (Opdivo) plus the investigational drug sitravatinib improved progression-free survival (PFS) in patients with pretreated metastatic clear-cell renal-cell carcinoma (RCC) and the historical disease control rates compared with nivolumab alone, according to the results of a phase 1/2 clinical trial reported at the 2020 Genitourinary Cancers Symposium.
San Francisco, CA—Treatment with the novel agent MK-6482 led to promising results in a phase 1/2 clinical trial of patients with metastatic clear-cell renal-cell carcinoma (RCC).

Chicago, IL—Tumor-specific antigens provide personalized targets for immunotherapy. Neoantigen vaccines are a new type of immunotherapy that can elicit immune response and achieve remission. Evidence is compelling to support neoantigens as the target of effective immune responses against cancer and to support an association between neoantigen load with improved clinical outcome, said Patrick Alexander Ott, MD, PhD, Clinical Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, at ASCO 2019.

High-grade gliomas harboring the histone 3 (H3) K27M mutation are lethal brain tumors associated with a poor prognosis.
Treatment options are few for patients with cholangiocarcinoma whose disease progresses while receiving first-line treatment with gemci­tabine (Gemzar) and cisplatin (Platinol), with no established second-line regimen.
“Tumor reductions and durable responses were observed in most patients, especially those whose cancers progressed with chemotherapy and multikinase inhibitors,” said Vivek Subbiah, MD, at the 2018 AACR meeting.
A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a preliminary phase 1b clinical trial.
Page 1 of 2
Results 1 - 10 of 14